1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures

 
• By Lucie Ellis-Taitt

Opdivo's Phase III disappointment in first-line non-small cell lung cancer (NSCLC) is not the end of the world for Bristol-Myers Squibb, according to Datamonitor Healthcare analyst Dustin Phan. It also may not be the last surprise in a field with so many contenders and so many ongoing trials, as data from Pharmaprojects shows.

Lung cancer concept

Bristol-Myers Squibb Co. shocked the market late last week when it announced a Phase III trial exploring its market leading PD-1 inhibitor Opdivo (nivolumab) as a first-line treatment for NSCLC had missed its primary endpoint. However, Datamonitor Healthcare analyst Dustin Phan told Scrip Opdivo will still pose a barrier to market entry for many late-phase pipeline therapies because of its strong uptake as a second-line treatment.

Topline data from the pivotal Phase III CheckMate 026 trial revealed that Opdivo failed to meet its primary endpoint of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

More from Therapy Areas

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 
• By Sushmita Panda

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.